Health: What Is It Worth?: Measures of Health Benefits is a collection of papers that tackles concerns in health care services and health benefit systems. The title first deals with the measure of health status, along with the policy that governs it and the results of contemporary biomedical research. The text also covers the approaches for the assessment of long-term care. The next part talks about valuing health and health benefits. Next, the selection deals with a method for the computation of the social rate of returns derived from investments in biomedical research. The last part discusses the concerns in health resource allocation. The book will be of great interest to the legislative bodies of governments, health officials, and health professionals.

Medicine, morals and money have, for centuries, lived in uneasy cohabitation. Dwelling in the social institution of care of the sick, each needs the other, yet each is embarrassed to admit the other's presence. Morality, in particular, suffers embarrassment, for it is often required to explain how money and medicine are not inimical. Throughout the history of Western medicine, morality's explanations have been con sistently ambiguous. Pla.o held that the physician must cultivate the art of getting paid as well as the art of healing, for even if the goal of medicine is healing and not making money, the self-interest of the craftsman is satisfied thereby [4]. Centuries later, a medieval medical moralist, Henri de Mandeville, said: "The chief object of the patient ... is to get cured ... the object of the surgeon, on the other hand, is to obtain his money ... ([5], p. 16). This incompatibility, while general, is not universal. Throughout history, medical practitioners have resolved the problem - either in conscience or to their satisfaction. Some physicians have been so reluctant to make a profit from the ills of those whom they treated that they preferred to live in poverty. Samuel Johnson described his friend, Dr. Robert Levet, a Practiser of Physic: No summons mock'd by chill delay, No petty gain disdain'd by pride; The modest wants of ev'ry day The toil of ev'ry day supplied [3].

The Price of Global Health is a unique book that describes the pharmaceutical pricing process and its business, economic and social challenges. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death? The pharmaceutical industry is under unprecedented pressure due to a combination of declining R&D productivity, payer/provider demands for better value and public pressures to show pricing restraint. Rapidly increasing cost of healthcare, shifts from fee-for-service to value-based reimbursement, public pressure on drug pricing and an increasingly vocal medical community have empowered public and private payers worldwide to be more demanding on evidence of value for the prescription drugs that are brought to market. Pharmaceutical companies have often failed to deliver evidence of patient value, as development decision-making is overly focused on speed to FDA approval rather than speed to commercial success by effectively addressing the many “Access Journey” obstacles that typify today’s much changed pharmaceutical environment. This 3rd edition is significantly expanded with ten new chapters and revised and updated throughout to reflect today’s environment. The contents are reorganized to directly address critical pricing and patient access issues. Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences from healthcare industry professionals to policy makers, consumers, pharmaceutical company leaders and access and pricing professionals to gain a better understanding of this highly complex and emotionally charged field.

The Price of Global Health is a unique, much-needed and invaluable resource for anybody interested or involved in, or affected by, the development, funding and use of prescription drugs. The second edition includes new chapters on payer value story development, oncology, orphan drugs and payer negotiations. Country chapters have also been updated to reflect changes in healthcare systems, including the Affordable Care Act in the US, AMNOG in Germany, and medico-economic requirements in France. Almost every chapter has been updated with new examples and illustrations.

The objectives of this study are to describe experiences in price setting and how pricing has been used to attain better coverage, quality, financial protection, and health outcomes. It builds on newly commissioned case studies and lessons learned in calculating prices, negotiating with providers, and monitoring changes. Recognising that no single model is applicable to all settings, the study aimed to generate best practices and identify areas for future research, particularly in low- and middle-income settings. The report and the case studies were jointly developed by the OECD and the WHO Centre for Health Development in Kobe (Japan).

Medical research, with its power to attract money and political support, and its promise of cures for a wide range of medical burdens, has good and bad sides--which are often indistinguishable. In this book, the author teases out the distinctions and differences, revealing the difficulties that result when the research imperative is suffused with excessive zeal, adulterated by the profit motive, or used to justify cutting moral corners. Exploring the National Institutes of Health's annual budget, the inflated estimates of health care cost savings that result from research, the high prices charged by drug companies, the use and misuse of human subjects for medical testing, and the controversies surrounding human cloning and stem cell research, he clarifies the fine line between doing good and doing harm in the name of medical progress. His work shows that medical research must be understood in light of other social and economic needs and how even the research imperative, dedic.

This 1991 book is a history of political conflict over health policy in Australia, providing background to an ongoing debate.

Babies of women with diabetes are nearly five times more likely to be stillborn and almost three times more likely to die in the first three months. The incidence of gestational diabetes mellitus in the U.S. is high—between 3 and 7 percent—and rising. The condition is often complicated by other risk factors such as obesity and heart disease. The Textbook of Diabetes and Pregnancy presents a comprehensive review of the science, clinical management, and medical implications of gestational diabetes mellitus, a condition with serious consequences that is on the increase in all developed societies. This new edition supports the latest initiatives and strategies of the International Federation of Gynecology and Obstetrics (FIGO) and adds chapters on noncommunicable diseases, obesity, bariatric surgery, and epidemiology outside Western cultures. Written by a cadre of experts, the book provides a comprehensive, authoritative, and international view of gestational diabetes mellitus and will be invaluable to maternal-fetal medicine specialists, diabetologists, neonatologists, and a growing number of gynecologists and general physicians concerned with the management of noncommunicable diseases in pregnancy.